Latigo Biotherapeutics

Private

#Pain management #Neurology #Non-opioid analgesics

Latigo Biotherapeutics is a clinical-stage biotechnology company developing non-opioid pain drugs that target sodium ion channels. The company recently outlined plans to go public on NASDAQ under ticker LTGO.

Company Info

Sector:Biotechnology

Headquarters:Westlake Village, California, USA

Founded:2018

Website:latigobio.com/

Funding & Investor Relations

IPO Outlook / Plans

NASDAQ IPO planned (ticker LTGO)

Upcoming Milestones & Key Dates

2026 H2

Financing

NASDAQ IPO (LTGO)

Q4 2026

Clinical

Phase 1 readout

Clinical Development Pipeline

LTGO-33

Target: Nav1.7 sodium channel

Acute pain

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Undisclosed

Target: Nav1.8 sodium channel

Chronic pain

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Undisclosed

Target: TBD

Neuropathic pain

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Pain drugmaker Latigo outlines plans to go public ↗

Pain drugmaker Latigo outlined plans to go public on NASDAQ under ticker LTGO.

Leadership Team

To be confirmed

Chief Executive Officer

To be confirmed

Chief Medical Officer

To be confirmed

Chief Scientific Officer

Careers & Job Openings

See all open roles

Various

Westlake Village, CA

Apply Now →